Pain

Prolonged exposure to the over the counter medicine was associated with a 30% increase in the relative risk of ADHD and a 20% increase in the relative risk of ASD.

R. Presley Swann, MD discussed his preference for CPNBs when treating his patient's post-operative pain.

Trial results on the recently FDA-approved gammaCore device will be presented at the American Academy of Neurology (AAN) annual meeting.

Study results show 30.3% of difficult to treat patients taking erenumab saw at least a 50% reduction in monthly migraine days.

The likelihood that a patient would receive a new opioid prescription was higher for at-risk patients and remained true even after adjusting for demographic characteristics, comorbidities, and diagnoses associated with pain.

The therapy regimen is tolerable, safe, and effective for patients attempting to detoxify for an extended opioid agonist treatment.

Those who frequently use illicit drugs in public places were more likely to witness overdoses, and thus should be targeted for naloxone treatment training.

The Prescription Drug User Fee Act goal date, which was originally set for Q2 of 2018 after the therapy was granted Priority Review designation, has now been pushed 3 months, to Q3.

The long-acting, single-dose nerve block can now be used for popularizing procedures such as total shoulder arthroplasty or rotator cuff repair.

In a first-time issuance, all food products containing powdered kratom from Triangle Pharmanaturals, have been ordered to be recalled due to samples containing salmonella bacteria.

Researchers observed that prescribing rates were cut by about 6% in at-risk populations from states with legalization laws in place.

A study has shown that those who underestimated their prescription rates decreased opioid prescriptions by 2.2 patients more over the next 12 months after being notified of their data.

The placebo-controlled study found that the supplement reduced physiological as well as psychological symptoms of PMS.

A CDC analysis found that overall drug overdose death rates increased by 21.5%, but those involving synthetic opioids more than doubled.

Analysis including 2,848,768 deaths since 1980 has revealed increases in mortality rates due to drug abuse disorders, as well as increases in rates for self-harm and alcohol use disorders since 2000.

A new study found that NAS rates have increased 433% from 2004 to 2014.

Researchers in Pennsylvania want to bolster the scientific case for the use of medical marijuana as an alternative to opioids.

Although LY2828360 failed as a therapeutic option for osteopathic pain in phase 2, it may be granted new life as a neuropathic pain treatment.

This week on MDNN: America trends toward healthier outcomes, the first-ever gene therapy procedure was performed, and President Donald Trump declared his stance on opioid traffickers.

Underscoring a commitment to make health care accessible to all populations, the Kraft Center for Community Health at Massachusetts General Hospital recently launched CareZone—a mobile clinic aimed at engaging and treating those struggling with opioid use disorder and related health issues.

If approved, NTX-011 may help combat the nationwide opioid epidemic.

These findings could be the first step in the design of therapies that are better able to target specific receptors to exert therapeutic effects.

The president's remarks in New Hampshire Monday called for judicial action and a law enforcement-centric approach to the opioid epidemic.

Lead researcher Ben Seymour, PhD, noted that this brings medicine a step closer to harnessing the brain's natural pain relief system in a more specific way.

A new study based on self-reports by medical cannabis patients in Minnesota shows 42% achieved meaningful pain relief.